ADAR1 Capital Management »

Keros Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Keros Therapeutics (KROS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Keros Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Keros Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Keros Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $22M 338k 66.20
2023-12-31 $27M 688k 39.76

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Keros Therapeutics

BlackRock
BlackRock
Vanguard Group
Darwin Global Management
T. Rowe Price Associates
State Street Corporation
OrbiMed Advisors
Point72 Asset Management
Leucadia National Corporation
TCG Crossover Management
Holocene Advisors
Woodline Partners
Geode Capital Management
Citadel Advisors
Braidwell

View all funds holding Keros Therapeutics